Carla de Boer

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 690 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 175 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

Bertram Wiedenmann, Peter Malfertheiner, Helmut Friess et al. · PubMed · 2008 · 144 citations

Medicine, Oncology, Pharmacotherapy +16

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Ajai Chari, Joaquín Martínez‐López, María‐Victoria Mateos et al. · Blood · 2019 · 132 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11